Features | Partner Sites | Information | LinkXpress
Sign In
SCHILLER AG
AMPRONIX
TERARECON, INC.

PET-CT Identifies Ruptured and High-Risk Coronary Plaque

By Medimaging International staff writers
Posted on 09 Jan 2014
Image: The Biograph mCT PET-CT system by Siemens Healthcare (Photo courtesy of Siemens Healthcare).
Image: The Biograph mCT PET-CT system by Siemens Healthcare (Photo courtesy of Siemens Healthcare).
Scientists have discovered that the tracer 18F-sodium fluoride (18F-NaF) used with positron emission tomography-computed tomography (PET-CT) imaging technology is the first noninvasive imaging modality to identify and localize ruptured and high-risk coronary plaque.

The University of Edinburgh (Scotland, UK) is leading the heart disease study with the help of a Biograph mCT PET-CT system developed by Siemens Healthcare (Erlangen, Germany). The new study’s findings were published October 2013 in the Lancet. Currently there is no noninvasive way of finding high-risk plaques at risk of rupturing and causing a heart attack. The imaging technology is providing new clues into clinical research into early diagnosis of the disorder.

In the prospective clinical trial, patients with myocardial infarction and stable angina underwent 18F-NaF and 18F-fluorodeoxyglucose (18F-FDG) PET-CT and invasive coronary angiography. 18F-NaF uptake was compared with histology in carotid endarterectomy specimens from patients with symptomatic carotid disease, and with intravascular ultrasound in patients with stable angina. The primary endpoint was the comparison of 18F-fluoride tissue-to-background ratios of culprit and non-culprit coronary plaques of patients with acute myocardial infarction.

In 93% (37) of patients with myocardial infarction, the highest coronary 18F-NaF uptake was seen in the culprit plaque. By contrast, coronary 18F-fluorodeoxyglucose (FDG) uptake was typically concealed by myocardial uptake and where discernible, there were no differences between culprit and non-culprit plaques. Marked 18F-NaF uptake occurred at the site of all carotid plaque ruptures and was linked with histologic evidence of active calcification, macrophage infiltration, apoptosis, and necrosis. Forty-five percent (18) of patients with stable angina had plaques with focal 18F-NaF uptake that were associated with more high-risk features on intravascular ultrasound than those without uptake.

The plaque areas in the blood vessels were easily identifiable by using the Biograph mCT scanner. In the patients with angina, advanced notice that they had high-risk plaques and a heart attack may be impending. These patients could then be targeted with aggressive therapy to avoid future events.

“Being able to identify dangerous fatty plaques likely to cause a heart attack is something that conventional heart tests can’t do. This research suggests that PET-CT scanning may provide an answer, identifying ‘ticking time bomb’ patients at risk of a heart attack,” said Prof. Peter Weissberg, medical director at the British Heart Foundation (BHF; London, UK). “Nearly 20 years of BHF-funded research has led us to this point. We now need to confirm these findings, and then understand how best to use new tests like this in the clinic to benefit heart patients.”

BHF clinical lecturer and cardiologist Dr. Marc Dweck, who led the research at the University of Edinburgh, stated: “We have developed what we hope is a way to ‘light up’ plaques on the brink of rupturing and causing a heart attack. If we could know how close a person is to having a heart attack, we could step in with medication or surgery before the damage is done. This is a first step towards that goal. The next stage is to confirm these findings in larger studies to establish first that this technique can truly predict heart attacks and secondly that treatment can help patients avoid these events.”

“Siemens Healthcare is delighted that the Biograph mCT is aiding ground-breaking research into the UK’s biggest killer—heart disease,” remarked Lawrence Foulsham, business manager, molecular imaging at Siemens Healthcare. “The condition is a clinical priority for the UK; therefore advancements in this field are incredibly important. We have a long-standing partnership with the Clinical Research Imaging Center at the University of Edinburgh and look forward to assisting them with further clinical research insights into the future.”

The Clinical Research Imaging Center at the University of Edinburgh installed the Biograph mCT in 2010.

Related Links:

Siemens Healthcare
University of Edinburgh



SuperSonic Imagine
RTI ELECTRONICS AB
RADCAL

Channels

MRI

view channel
Image: The quantitative character of the novel 3D technique on MR scans from a patient with primary liver cancer is demonstrated. Images A and B show the scan of the patient before being treated with chemoembolization. The new 3D technique helped quantify the volume and distribution of viable tumor tissue (shown in red and yellow colors). Images C and D demonstrate MR scans acquired after the treatment. The new 3D method helped the radiologists to quantify the vast central destruction of the tumor after the treatment (the dead tumor is represented by the blue color) (Photo courtesy of Johns Hopkins Medicine).

3D MRI Offers Improved Prediction of Survival After Chemotherapy for Liver Tumors

Researchers are using specialized three-dimensional (3D) magnetic resonance imaging (MRI) scanning technology to accurately measure living and dying liver tumor tissue in order to quickly show whether... Read more

Ultrasound

view channel
Image: Siemens Healthcare has launched the HELX Evolution, the newest iteration of its Acuson S range of ultrasound imaging systems (Photo courtesy of Siemens Healthcare).

Ultrasound Imaging System Enhancements Include High Definition Transducers, Sophisticated Elastography, and Tissue Strain Analysis

New features designed for a range of ultrasound systems include enhanced image quality with a large 21.5-inch liquid crystal diode (LCD) monitor, high definition (HD) transducers, optimized contrast agent... Read more

Nuclear medicine

view channel
Image: Sagittal section of brain PET image at four hours after 64CuCl2 injection with disulfiram or D-penicillamine in MD model mice (Photo courtesy of the RIKEN Center for Life Science Technologies).

PET Imaging Used to Assess Effectiveness of Menkes Disease Treatments

Japanese scientists are using positron emission tomography (PET) imaging to visualize the distribution of copper in the body using lab mice. Copper distribution is deregulated in a genetic disorder called... Read more

General/Advanced Imaging

view channel

Secondary Light Emission Generated by Plasmonic Nanostructures May Improve Medical Imaging Technology

New clues into light emission at different wavelengths generated by elements known plasmonic nanostructures may help to improve medical imaging technology. A plasmon is a quantum of plasma oscillation. The plasmon is a quasiparticle resulting from the quantization of plasma oscillations just as photons, and phonons are... Read more

Imaging IT

view channel

Software Designed for the Assessment of Orthopedic Implant Fixation and Bone Segment Motion

Model-based roentgen stereophotogrammetric analysis (MBRSA) software has been developed for evaluation of orthopedic implant fixation and bone segment motion. The software is the first to measure the in vivo three-dimensional (3D) position and/or relative motion of metal implants, markers beads, and/or bone segments in... Read more

Industry News

view channel

Collaboration Expands Capacity for Proton Therapy Clinical Research and Patient Treatments

Varian Medical Systems (Palo Alto, CA, USA) and the Paul Scherrer Institute (PSI; Villigen PSI, Switzerland) are extending an existing collaboration in the field of proton therapy to offer patients more accurate cancer treatments using intensity-modulated proton therapy (IMPT). Under the agreement, Varian will also... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.